ULTRAGENYX
LIVE

Serial Number

97980518

Owner

Ultragenyx Pharmaceutical Inc.

Attorney

Brian Focarino

First Use Date

Feb 24, 2023

Filing Date

Dec 21, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ULTRAGENYX Trademark

Serial Number: 97980518 • Registration: 7907676

ULTRAGENYX is a trademark filed by Ultragenyx Pharmaceutical Inc. on December 21, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 16 (Paper Goods). The application is currently registered and active.

Owner Contact Info

Ultragenyx Pharmaceutical Inc. (60 trademarks)

Novato, CA 94949

Entity Type: 03

Trademark Details

Filing Date

December 21, 2022

Registration Date

August 19, 2025

First Use Anywhere

February 24, 2023

First Use in Commerce

February 24, 2023

Published for Opposition

December 12, 2023

Goods & Services

Education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of rare diseases and disorders; online journals, namely, blogs featuring information on rare diseases and disorders

Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, inflammatory, autoimmune, musculoskeletal, ophthalmologic, respiratory, osteopathic, oncologic, endocrine, orthopedic, metabolic, lipid-related, genetic, neuromuscular, autosomal, lysosomal storage, enzyme, hematologic and long-chain fatty acid oxidation disorders (LC-FAOD) diseases and disorders; chemical, biological, and biochemical preparations for use in gene delivery technology for medical use, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for use in in vivo therapeutic use in gene therapy

Printed publications, namely, books, brochures, informational pamphlets, informational cards, and advertisements being signs and boards of paper in the field of rare diseases and disorders

Financial and insurance consultation services, namely, patient advisory, support and consultancy services regarding patient finances, insurance and access to medical treatment; providing financial and insurance information, namely, providing information and guidance in connection with health insurance benefit plans and other patient financial assistance resources; financial and insurance consultation services, namely, insurance and medical and pharmaceutical access consultation services, namely, assisting patients and their caregivers to identify the scope of coverage offered by patient medical and pharmaceutical insurance and to identify other financial assistance resources for payment of patient treatment; insurance consultation services, namely, assisting patients and their caregivers to obtain authorization and payment for medical and pharmaceutical costs

Chemical, biological, and biochemical preparations for use in gene delivery technology, namely, nucleic acids, including, coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for use in vitro laboratory use; chemical, biological, and biochemical preparations for use in the manufacture of pharmaceutical preparations

Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders; medical consulting services in the field of rare diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of rare diseases and disorders, and collecting data and information on rare diseases and disorders for screening, diagnosis and treatment purposes; medical information services in the nature of providing a database in the field of hypophosphatemia information based on collected patient data and information all for treatment and diagnostic purposes

Pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of rare diseases and disorders; medical and scientific research information in the field of rare diseases and disorders; computer services, namely, creating an on-line community for registered users to obtain feedback from their peers, interact with research data, and share data in the field of rare diseases and disorders; pharmaceutical research services, namely, recruitment of rare disease patients for panels such as pharmaceutical research panels; providing medical research and scientific research information in the field of hypophosphatemia

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 19, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 19, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jul 31, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jul 31, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jul 29, 2025 SUPC
DIVISIONAL PROCESSING COMPLETE
Jul 29, 2025 DPCC
SOU EXTENSION 2 GRANTED
Jul 29, 2025 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 24, 2025 AITU
USE AMENDMENT FILED
Jan 16, 2025 IUAF
DIVISIONAL REQUEST RECEIVED
Jan 16, 2025 DRRR
SOU EXTENSION 2 FILED
Jan 16, 2025 EXT2
TEAS STATEMENT OF USE RECEIVED
Jan 16, 2025 EISU
TEAS REQUEST TO DIVIDE RECEIVED
Jan 16, 2025 ERTD
SOU TEAS EXTENSION RECEIVED
Jan 16, 2025 EEXT
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Aug 2, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 2, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 2, 2024 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 2, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 2, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 2, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 2, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 6, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 12, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 12, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 22, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 6, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 3, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 3, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 3, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 25, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 25, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 25, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 21, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 18, 2023 NWOS
NEW APPLICATION ENTERED
Dec 24, 2022 NWAP